FUTURA MEDICAL PLC

• ◆

  Material uncertainty over going concern

  We draw attention to note 2.2 in the financial statements, which sets out that under the cash flow forecast, the group and parent company requires certain anticipated near-term cash inflows, including amounts expected from commercial arrangements, product sales and IP related milestones. In addition to these cash inflows there will be a need to raise additional funding before the end of 2026 in order to continue operations throughout the forecast period. These anticipated cash inflows and future financing arrangements are not secured at the date of approval of the financial statements.

• ◆

  3 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

• ·

  Going-concern uncertainty disclosed

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. FUTURA MEDICAL PLC 2001-07-11 → present
2. FUTURA (HOLDINGS) PLC 2001-04-25 → 2001-07-11

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Grant Thornton UK LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“We draw attention to note 2.2 in the financial statements, which sets out that under the cash flow forecast, the group and parent company requires certain anticipated near-term cash inflows, including amounts expected from commercial arrangements, product sales and IP related milestones. In addition to these cash inflows there will be a need to raise additional funding before the end of 2026 in order to continue operations throughout the forecast period. These anticipated cash inflows and future financing arrangements are not secured at the date of approval of the financial statements.”

Significant events

• “In December 2025, we completed a fundraise raising gross proceeds of £2.75 million, by way of an oversubscribed firm placing, conditional placing and subscription.”
• “On January 15 2026, the Company's Board of Directors approved a special long-term incentive award for employees in the form of share options over ordinary shares under the Company's Long-Term Incentive Plan.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

13

last 12 months

Capital events

7

last 24 months

Officers appointed

1

last 12 months

Officers resigned

3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.